- Home
- TYRA vs CASS Comparison
TYRA vs CASS Comparison
Compare TYRA & CASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- CASS
- Stock Information
- Founded
- TYRA 2018
- CASS 1906
- Country
- TYRA United States
- CASS United States
- Employees
- TYRA 38
- CASS N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- CASS Business Services
- Sector
- TYRA Health Care
- CASS Consumer Discretionary
- Exchange
- TYRA Nasdaq
- CASS Nasdaq
- Market Cap
- TYRA 666.4M
- CASS 588.1M
- IPO Year
- TYRA 2021
- CASS 1996
- Fundamental
- Price
- TYRA $13.17
- CASS $43.18
- Analyst Decision
- TYRA Strong Buy
- CASS Buy
- Analyst Count
- TYRA 6
- CASS 1
- Target Price
- TYRA $30.50
- CASS $45.00
- AVG Volume (30 Days)
- TYRA 247.2K
- CASS 43.1K
- Earning Date
- TYRA 03-18-2025
- CASS 04-17-2025
- Dividend Yield
- TYRA N/A
- CASS 2.86%
- EPS Growth
- TYRA N/A
- CASS N/A
- EPS
- TYRA N/A
- CASS 1.39
- Revenue
- TYRA N/A
- CASS $219,894,000.00
- Revenue This Year
- TYRA N/A
- CASS N/A
- Revenue Next Year
- TYRA N/A
- CASS $7.70
- P/E Ratio
- TYRA N/A
- CASS $31.22
- Revenue Growth
- TYRA N/A
- CASS 3.13
- 52 Week Low
- TYRA $11.89
- CASS $37.99
- 52 Week High
- TYRA $29.60
- CASS $49.16
- Technical
- Relative Strength Index (RSI)
- TYRA 43.64
- CASS 51.44
- Support Level
- TYRA $12.27
- CASS $42.30
- Resistance Level
- TYRA $13.79
- CASS $45.45
- Average True Range (ATR)
- TYRA 0.71
- CASS 1.10
- MACD
- TYRA 0.03
- CASS 0.08
- Stochastic Oscillator
- TYRA 51.09
- CASS 55.84
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About CASS Cass Information Systems Inc
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment.